Ignite Creation Date:
2024-05-06 @ 2:18 PM
Last Modification Date:
2024-10-26 @ 1:28 PM
Study NCT ID:
NCT04274933
Status:
TERMINATED
Last Update Posted:
2020-10-29
First Post:
2020-02-17
Brief Title:
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK46 Inhibitor Therapy
Sponsor:
AbbVie
Organization:
AbbVie
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-05-21
Start Date Type:
ACTUAL
Primary Completion Date:
2020-10-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-10-08
Completion Date Type:
ACTUAL
First Submit Date:
2020-02-17
First Submit QC Date:
February 17 2020
Study First Post Date:
2020-02-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-10-28
Last Update Post Date:
2020-10-29
Last Update Post Date Type:
ACTUAL